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Radical cystectomyPurpose: Adding novel drugs like pregabalin to analgesic regimens might reduce postoperative pain, total
opioid consumption and side effects, this study compares multiple doses of pregabalin for postoperative
analgesia following radical cystectomy.
Methods: This study is registered at www.clinicaltrials.gov at no.: NCT02724293. Sixty patients were ran-
domized into 4 groups: Group I: control (placebo) group, Group II: received pregabalin 300 mg 2 h pre-
operatively, Group III: received pregabalin 300 mg 2 h preoperatively and 12 h thereafter, Group IV:
received pregabalin 600 mg 2 h preoperatively. Postoperative pain, time to first request of analgesia,
and total morphine consumption were recorded.
Results: VAS was significantly reduced in groups II, III, IV in comparison with group I immediately post-
operative, and after 2 h (P < 0.05). Sedation score was significantly higher in groups II, III, IV compared to
group I immediately postoperative (P < 0.05). First request of analgesia was significantly delayed in
groups II, III, IV compared to control group (P = 0.000). Total analgesic consumption was significantly
reduced in groups II, III, IV compared to group I (P = 0.000). Group IV showed a significantly higher inci-
dence of dizziness compared to group I.
Conclusion: Peri-operative pregabalin at doses of 300 mg and 600 mg reduced postoperative opioid con-
sumption and prolonged time to first request of analgesia in patients who underwent radical cystectomy,
and a single preoperative dose of 600 mg is superior in analgesia to others, without serious side effects.
 2016 Publishing services by Elsevier B.V. on behalf of Egyptian Society of Anesthesiologists. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Numerous studies have explored undesirable effects of unre-
lieved pain with maximum effects on different body systems.
These effects include adrenal sympathetic hyperactivity, myocar-
dial ischemia, deep venous thrombosis, difficulty of breathing,
atelectasis, tachycardia, hypertension, and others [1].
Opioids represent the cornerstone in postoperative pain man-
agement despite serious side-effects [2] that might impair patient
recovery after surgery [3].
Multimodal postoperative analgesic regimens may decrease the
incidence of complications, shorten the requirement for hospital-
ization, and decrease recovery times and health costs [4].
Pregabalin is a structural analogue of the inhibitory neurotrans-
mitter gaba-aminobutyric acid, with anticonvulsant, anti-
hyperalgesic, and anxiolytic properties such as gabapentin, butwith a more favorable pharmacokinetic profile [5,6]. There are sev-
eral reports for the use of pregabalin in the management of postop-
erative pain with a positive result in a variety of surgical models
[7–9].
Thus, using novel adjuvant drugs such as pregabalin, as a part of
a multimodal analgesic regimen, might be reasonable for lowering
postoperative pain scores, decreasing total opioid consumption,
and hence, side effects [10,11].
Till now, there is no agreement upon the ideal dose of prega-
balin when used as an adjuvant to a multimodal analgesic protocol
for postoperative analgesia following major surgery. This random-
ized, double-blinded, controlled study was designed to examine
the analgesic efficacy of three different pre/peri-operative doses
of pregabalin following radical cystectomy and urinary diversion
in comparison with placebo, in search of the ideal dosage.2. Patients and methods
This prospective, randomized, double-blinded, controlled study
was started after Institutional Ethics Committee approval (South
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written informed consent from all participating patients. It is reg-
istered at www.clinicaltrials.gov at no.: NCT02724293. The study
was conducted according to the most recent version of the Decla-
ration of Helsinki. Sixty patients between the ages of 18 and
60 years with ASA I-II physical status who underwent radical cys-
tectomy under general anesthesia were enrolled in this study.
Patients were randomized into 4 groups (15 patients in each):
Group I: control group (placebo group).
Group II: patients received pregabalin 300 mg 2 h
preoperatively.
Group III: patients received pregabalin 300 mg 2 h preopera-
tively and 12 h after the preoperative dose.
Group IV: patients received pregabalin 600 mg 2 h
preoperatively.
Randomization was done using lottery method. Pregabalin was
given orally by a staff nurse who was not included in the study.
Anesthesiologists and patients were blinded to the groups.
2.1. Exclusion criteria
Patients with a history of drug or alcohol abuse and patients
with chronic pain or daily intake of analgesics, uncontrolled dia-
betes mellitus and/or hypertension, atherosclerotic heart disease,
seizures, impaired kidney or liver functions, body mass index
P35 kg/m2, and who could not control a patient-controlled analge-
sia (PCA) device were excluded from the study.
2.2. Anesthetic management and operation
One day before surgery, patients were trained on how to use the
PCA pump that when they feel pain, a push to the button will
relieve it, but they cannot push the button frequently to avoid
overdose (lock out period). They were also taught how to express
the level of pain they experience using an 11-point Visual Ana-
logue Scale (VAS), with 0 indicating no pain and 10 indicating
the worst imaginable pain. On arrival to the operating room, an
intravenous line was inserted. Patients were pre-medicated with
0.25 mg/kg intravenous ranitidine. Monitoring included electrocar-
diography, noninvasive blood pressure (NIBP), O2 saturation, and
temperature. Anesthesia was induced for all participating patients
with 1.5–2 lg/kg fentanyl, 1–2.5 mg/kg propofol, and 1.5 mg/kg
lidocaine. Endotracheal intubation was facilitated by 0.15 mg/kg
cis-atracurium. Anesthesia and muscle relaxation were maintained
by 1–1.5 MAC isoflurane in 50% oxygen/air mixture and 0.03 mg/kg
cisatracurium, respectively, and mechanical ventilation was main-
tained in parameters that keep ETCo2 in the range of 35–40 mmHg.
Intravenous crystalloid solution was infused at a rate of 8 mL/kg/h
to correct for third space loss apart from added losses, and blood
transfusion was allowed when hemoglobin is <10 g/dl, or when
hematocrit value is <30%.
2.3. Patient controlled analgesia and pain scores
At theendof surgery, residualneuromuscularparalysiswasantag-
onized with neostigmine 0.04 mg/kg and atropine 0.02mg/kg.
The patients were connected to a morphine patient controlled
analgesia (PCA) pump (Perfusor Space PCA Infusion Pump System,
B. Braun, USA) on arrival at the PACU. The PCA pump was set to
deliver a loading dose of 2.5 mg and an incremental dose of
2.5 mg at a lockout interval of eight minutes and a four-hour limit
of 50 mg. Sedation level was evaluated using a 4-point sedation
scale where 0 = awake, 1 = easily aroused, 2 = awakens after tactile
stimulation, 3 = awakens after verbal stimulation, and 4 = notarousable [12]. Vital signs, visual analogue scale (VAS), total mor-
phine consumption and adverse effects such as nausea, vomiting,
pruritus, headache, dizziness, and visual abnormalities (double or
blurred) were recorded.
Our primary outcome measure was the efficacy of the studied
doses in reducing postoperative total analgesic consumption. Sec-
ondary outcome measures included reduction of postoperative
pain scores, time to first request of rescue analgesia, and the toler-
ability of the used doses represented by the side effects during the
follow-up period of 24 h.3. Statistical analysis
3.1. Power of the study
The primary end point was the total dose of intravenous PCA
morphine consumption in the first 24 h postoperatively. Secondary
endpoints were the safety profile of the studied doses in terms of
predefined adverse events, nausea, vomiting, and level of sedation
during the study period. A calculated sample size of 12 patients in
each group would have an 80% power of detecting a difference of
20% decrease in intravenous PCA morphine consumption at a
0.05 level of significance using a confidence interval of 95%. We
enrolled 15 patients in each group to compensate for possible
dropouts.
3.2. Data analysis
Analysis was performed using statistical package for the Social
Sciences software, ver. 20 (SPSS Inc., Chicago IL, USA). Data were
presented as mean ± SD, numbers, and percentages. Mann-
Whitney was used to compare between each two groups.
Chi-square test was used for comparison between percentages
and frequencies. P < 0.05 was considered significant.4. Results
This study was conducted on 60 patients who underwent radi-
cal cystectomy for management of urinary bladder cancer. Patients
were given different doses of perioperative pregabalin in order to
investigate its analgesic efficacy and safety.
Regarding the demographic and clinical data of the participat-
ing patients, there was no significant difference between group I
(control group) and the study groups II, III, IV Table 1.
Looking into the hemodynamic changes and changes in arterial
oxygen concentration in the intra-, and post-operative periods,
there was no significant difference between study groups II, III,
IV, and the control group I Figs. 1–4.
VAS showed a significant reduction in groups II, III, IV in com-
parison with control group I immediately postoperative, and after
2 h (P < 0.05). After that time, VAS values did not significantly differ
between the four study groups till the end of the 24 h of observa-
tion Fig. 5.
Sedation score was significantly higher in groups II, III, IV in
comparison with the control group I immediately postoperative
(P < 0.05). Two hours postoperatively, only group IV (600 mg pre-
gabalin) continued to show significantly higher sedation score
compared to control group I (P = 0.005). After 12 h postoperatively,
only group III (300 mg pregabalin twice) showed a significantly
higher sedation score compared to control group (P = 0.028). Fig. 6.
First request of rescue analgesic was significantly delayed in
groups II, III, IV in comparison with control group (P = 0.000)
Table 2. First request of analgesia was also significantly delayed
in groups III and IV compared to group II, and in group IV compared
to group III (P = 0.000).
Table 1
Personal and clinical data.
Group I (n = 15) Group II (n = 15) Group III (n = 15) Group IV (n = 15) P-value
Mean ± SD Mean ± SD Mean ± SD Mean ± SD I vs. II I vs. III I vs. IV
Age 47.80 ± 7.23 54.53 ± 8.56 54.20 ± 10.65 53.33 ± 10.30 0.136 0.067 0.170
Sex: No. (%) 0.598 0.682 –
Male 12 (80.0%) 14 (93.3%) 10 (66.7%) 12 (80.0%)
Female 3 (20.0%) 1 (6.7%) 5 (33.3%) 3 (20.0%)
Weight 73.73 ± 11.07 79.93 ± 10.74 78.33 ± 15.69 76.27 ± 14.61 0.146 0.229 0.709
Duration of surgery min 252.27 ± 30.50 273.29 ± 74.77 256.75 ± 48.11 266.73 ± 24.52 0.662 0.527 0.158
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Figure 1. Systolic blood pressure.
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Figure 2. Diastolic blood pressure.
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Figure 3. Pulse rate.
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Figure 4. Oxygen saturation.
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Figure 5. VAS score.
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Figure 6. Sedation score.
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Table 2
First request of analgesia and total analgesic consumption.
Group I
(n = 15)
Group II
(n = 15)
Group III
(n = 15)
Group IV
(n = 15)
P-value
Mean ± SD Mean ± SD Mean ± SD Mean ± SD I vs. II I vs. III I vs. IV II vs.
III
II vs.
IV
III vs.
IV
First analgesic request after
(hours)
1.20 ± 0.70 4.89 ± 1.98 4.38 ± 3.25 9.93 ± 2.73 0.000⁄ 0.000⁄ 0.000⁄ 0.001⁄ 0.025⁄ 0.042⁄
Total morphine consumption
(mg)
16.67 ± 4.50 7.07 ± 2.90 6.25 ± 3.42 5.33 ± 3.99 0.000⁄ 0.000⁄ 0.000⁄ 0.814 0.631 0.522
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groups II, III, IV in comparison with group I (P = 0.000). Table 2.
On comparing groups II, III and IV, there was no significant differ-
ence between them (P > 0.05).
Considering the side effects experienced by patients in different
groups during the study, a significantly lower number of patients
had vomiting in group IV (0 patients) compared to group I (6
patients) (P = 0.022). On the other hand, group IV showed a signif-
icantly higher incidence of dizziness (7 patients) compared to the
groups I and II (1 patient) (P = 0.039) Table 3.5. Discussion
This double-blinded, prospective, controlled trial investigated
the efficacy and safety of three different doses of pre/peri-
operative pregabalin for postoperative pain management in
patients who underwent radical cystectomy.
We found that there was a significant reduction of postopera-
tive VAS score (in the first two hours), total rescue analgesic con-
sumption, and delay of first request of recue analgesia in all the
study groups compared to the control group. Sedation was signifi-
cantly higher in all groups compared to control.
Prevention and treatment of postoperative pain continues to be
a major challenge in the postoperative period upon which early
mobilization and well-being of the surgical patients depend.
Gabapentinoids are recently used for postoperative analgesia. Pre-
gabalin is claimed to be more effective in preventing neuropathic
component of acute postoperative pain, and to produce more opi-
oid sparing effect than gabapentin.
The probable mechanism of action of pregabalin is through
potent binding at a2-d subunit of the presynaptic, voltage-gated
calcium channels that are widely distributed throughout the
peripheral and central nervous systems [11,13], and this reduces
calcium influx and therefore reduces the release of several neuro-
transmitters at nerve terminals including glutamate, nore-
pinephrine and substance P [14,15]. Also, it reduces the
hyperexcitability of dorsal horn neurons, the sensitization of which
is a component in acute pain models [16,17]; thus, pregabalin may
have a role in postoperative pain management [18,19].
So far, analgesic properties of pregabalin have been tested only
in controlled randomized trials conducted in patients of dentalTable 3
Side effects.
Side effects Group I
(n = 15)
Group II
(n = 15)
Group III
(n = 15)
Group
(n = 15
No. % No. % No. % No.
N/V 6 40.0 1 6.7 1 6.7 0
Pruritus 3 20.0 0 0.0 0 0.0 0
Headache 0 0.0 0 0.0 1 6.7 4
Dizziness 1 6.7 1 6.7 3 20.0 7
Visual abnormalities 0 0.0 0 0.0 1 6.7 2
* Significant difference (P < 0.05).pain, minor and day-case gynecological surgery, laparoscopic hys-
terectomy and hip arthroplasty [20–23].
As most of the previous studies found that the peri-operative
use of pregabalin at doses less than 300 mg had no analgesic effi-
cacy, and that it did not have analgesic sparing effects, we used
higher doses. A dose of 600 mg given 2 h before surgery is not
exceeding the maximal daily dose of pregabalin, and it is expected
to be more effective in the management of postoperative pain after
a major surgery like radical cystectomy; however, side effects need
to be explored, especially in the first 24 h of postoperative period.
VAS values were significantly lower in all pregabalin groups II,
III, and IV compared to control group I in the first two hours of
the postoperative period. Moreover, there was a reduction in total
rescue analgesic (morphine) consumption in the three study
groups compared to control group. There was a significant delay
of first analgesic request in the three study groups compared to
control group and it was significantly delayed in group IV com-
pared to group III; this is most probably the effect of the large sin-
gle dose (600 mg) given to patients in group IV preoperatively;
however, this was not translated into a significant change in the
total amount of analgesic given to patients in these two groups
(groups III and IV with the larger pregabalin dose among the four
study groups), and this could be explained by the second dose of
pregabalin of 300 mg given to patients in group III after 12 h from
the initial dose which, in our opinion, enforced its analgesic effi-
cacy and reduced the need to rescue analgesia.
These findings are compatible with most of the studies carried
out in this respect, where, Hill and co-workers [24] found
300 mg pregabalin to be more effective than 50 mg pregabalin or
400 mg ibuprofen in attenuating pain after dental extraction.
Moreover, in a study done by Ittichaikulthol and colleagues [25],
they found that 300 mg 1 h before surgery, significantly reduced
pain scores and morphine consumption after abdominal hysterec-
tomy. Mathiesen et al. [23] concluded that Pregabalin resulted in a
50% reduction in 24 h postoperative morphine requirements, but it
was associated with a higher level of sedation compared to pla-
cebo. Likewise, Jokela et al. [21] found that peri-operative use of
pregabalin 600 mg (300 mg one hour before surgery, and 12 h after
first dose) was associated with reduction of postoperative oxy-
codone consumption. Remarkably, Akhavan-akbari et al., con-
firmed that even a single pre-operative oral dose of pregabalin
150 mg is an effective method for reducing postoperative painIV
)
P-value
% I vs. II I vs. III I vs. IV II vs. III II vs. IV III vs. IV
0.0 0.084 0.084 0.022⁄ – 0.309 0.309
0.0 0.224 0.224 0.224 – – –
26.7 – 0.309 0.107 0.309 0.107 0.327
46.7 – 0.591 0.039⁄ 0.591 0.035⁄ 0.121
13.3 – 0.309 0.464 0.309 0.464 0.543
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gery [26].
Sedation scores were significantly higher for the three groups
immediately postoperative in comparison with control group,
and in group IV it continued to be significantly higher in the first
2 h. This is mostly due to the larger dose of pregabalin used at this
group. Another increase at the sedation score was noticed after
12 h postoperatively in group III in comparison with control, which
could be attributed to the second dose of 300 mg pregabalin given
to patients in this group after 12 h from the first dose (nearly 2 h
before this measurement of sedation score).
Nausea and/or vomiting occurred in 6 patients in group I most
likely due to the effects of higher dose morphine used as a rescue
analgesic in this group in comparison with others, and dizziness
was of higher incidence in group IV (7 patients) in comparison with
group I (only 1 patient). Somnolence and dizziness are the two
most common side effects associated with gabapentin and prega-
balin [27]. This is usually not disabling and antianxiety effect has
been found to be beneficial in some studies [28].
This agrees with the findings of Jokela and colleagues, where
the degree of drowsiness was similar after perioperative adminis-
tration of diazepam 10 mg, pregabalin 300 mg, or 600 mg follow-
ing laparoscopic hysterectomy. The incidence of dizziness and
blurred vision was higher after perioperative administration of
pregabalin 600 mg during the first 24 h after surgery [21].
In a study by Ghai and colleagues, 600 mg pregabalin was asso-
ciated with excess somnolence up to 18–24 h after surgery. Further
cases were abandoned with 600 mg though most of these cases did
not require any analgesic in the first 24 h [29].
We believe that our work is limited by the small number of par-
ticipating patients, and the relatively short follow-up period of
24 h. However, we were much impressed with the postoperative
analgesic effect of a single high dose of pregabalin, especially in a
major surgery like radical cystectomy.
A dose of 600 mg used once 2 h before surgery provided effi-
cient analgesia and delayed first request of analgesia more than
in other groups, with an overall reduction of total opioid consump-
tion parallel to that of the 300 mg repeated after 12 h. The higher
sedation, and incidence of dizziness with this single-high dose,
was not extensive and required no intervention, and thus, we rec-
ommend this dose to be an integral part of the already-used post-
operative analgesic regimens
9. Conclusion
Peri-operative pregabalin at doses of 300 mg and 600 mg
reduced postoperative opioid consumption and prolonged time
to first request of analgesia in patients underwent radical cystec-
tomy, and a single preoperative dose of 600 mg is superior in anal-
gesia to others, without serious side effects.
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